Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan
The Journal of Dermatology · 26.07.2026
DOI: 10.1111/1346-8138.70406 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Dermatology, online erschienen am 26.07.2026. Verfasst von Yayoi Tada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University Hospital, Tokyo, Japan. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.
Abstract (Originalsprache)
Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized. Using a Japanese hospital‐based insurance claims database (Medical Data Vision Co. Ltd.), we conducted a retrospective cohort study for patients with these psoriasis subtypes who initiated systemic drug therapy between 2020–2023 and had a ≥ 12‐month observation period. Overall, 3965 patients with plaque psoriasis, 80 with erythrodermic psoriasis, and 128 with generalized pustular psoriasis were included (median age, 62–66 years). Most patients initiated systemic therapy with a single drug. A phosphodiesterase 4 inhibitor was the most frequently prescribed index treatment for plaque psoriasis (48.8%), whereas a vitamin A derivative was most commonly prescribed for erythrodermic and generalized pustular psoriasis (42.5% and 42.2%, respectively), suggesting a distinctive Japan‐specific prescription pattern. The median proportion of days covered for index treatment was nearly 100% across all subtypes. Among the index treatments, biologics generally showed longer time to discontinuation than oral medications. Elderly patients were more likely to receive a phosphodiesterase 4 inhibitor or a vitamin A derivative as index treatment than younger patients, and biologics were more commonly selected for patients with psoriatic arthritis than for those without. Early uptake of tyrosine kinase 2 inhibitor was observed in 2023. Over a median observation period of approximately 30 months, > 85% of patients received three or fewer lines of systemic drug therapy and approximately 50% remained on at least one systemic drug therapy throughout the study period. This first comprehensive Japanese claims database analysis of multiple psoriasis subtypes provides an updated real‐world treatment landscape in Japan and helps address an important evidence gap arising from rapidly evolving systemic treatment options and limited contemporary real‐world data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Teikyo University Hospital, Tokyo, Japan.
- Patient Safety & Pharmacovigilance, Research & Development Data & Quantitative Sciences, Takeda Pharmaceutical Company Limited, Osaka, Japan.
- Statistical & Quantitative Sciences, Research & Development Data & Quantitative Sciences, Takeda Pharmaceutical Company Limited, Osaka, Japan.
- Therapeutic Area Strategy Unit (Gastrointestinal & Inflammation), Takeda Pharmaceutical Company Limited, Osaka, Japan.
- Marketed Products Medical and Development, Chief Medical Office, Takeda Pharmaceutical Company Limited, Osaka, Japan.
ORCID-Profile: Yayoi Tada, Miyuki Hasegawa, Motonobu Sakaguchi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda
Förderung
- Takeda Pharmaceutical Company
Zitieren
APA
Tada, Y., Maeda, Y., Hasegawa, M., Sakaguchi, M., Hashimoto, T., Narusawa, T., Takabayashi, N., Takahashi, T., Kondo, T., & Kuroda, S. (2026). Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70406
Vancouver
Tada Y, Maeda Y, Hasegawa M, Sakaguchi M, Hashimoto T, Narusawa T, et al. Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70406
BibTeX
@article{Tada2026,
author = {Tada, Yayoi and Maeda, Yoshiko and Hasegawa, Miyuki and Sakaguchi, Motonobu and Hashimoto, Takamasa and Narusawa, Teruko and Takabayashi, Nobuyoshi and Takahashi, Tomoko and Kondo, Taisuke and Kuroda, Shingo},
title = {Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70406}
}
EUVIMED